Daily Management Review

AstraZeneca to buy rare diseases drugs developer for $39B


AstraZeneca will buy an American developer of drugs for rare diseases for $ 39 billion. This will strengthen the position of the creator of the Oxford vaccine in the treatment of complex diseases, including blood diseases.

D Wells
D Wells
The pharmaceutical company AstraZeneca has agreed to buy the American company Alexion Pharmaceuticals, which produces medicines for rare diseases. This follows from a press release on the AstraZeneca website.

The deal was valued at $ 39 billion, $ 175 per share. AstraZeneca will finance the deal partly with cash and partly with its depositary receipts: $ 60 and 2,1243 receipts per Alexion share. Alexion's price per share is quoted at a 45% premium to the company's value at the close of trading on Friday. The companies expect to secure regulatory approvals and close the deal in the third quarter of 2021.

The purchase of Alexion will allow AstraZeneca to strengthen its position in areas such as the treatment of blood diseases, Bloomberg explained. He noted that this fits into the strategy of AstraZeneca CEO Pascal Soriot, who has been developing profitable areas in the company since 2012.

AstraZeneca has worked with the University of Oxford to develop a vaccine against the coronavirus. It showed an average efficacy of 70%, less than the declared efficacy of other vaccines, such as those developed by Pfizer and BioNTech, Moderna and Russia's Sputnik V. 

source: bloomberg.com